Live Breaking News & Updates on Specialised therapeutics asia pte ltd

Puma Biotechnology (NASDAQ:PBYI) & Shattuck Labs (NASDAQ:STTK) Critical Review

Puma Biotechnology (NASDAQ:PBYI – Get Free Report) and Shattuck Labs (NASDAQ:STTK – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations and risk. Earnings & Valuation This table compares Puma […]

Texas , United-states , California , Los-angeles , Given-shattuck-lab , Pint-pharma-international , Shattuck-lab , Takeda-pharmaceutical-company , Knight-therapeutics-inc , Medison-pharma-ltd , Pfizer-inc , Puma-biotechnology-inc

Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countries

Agreement between Ascendis Pharma A/S and ST is for the exclusive distribution and commercialisation of three Ascendis Pharma endocrinology therapiesTwo of the therapies are already internationally.

Denmark , Australia , New-zealand , United-states , Thailand , Brunei , Malaysia , Singapore , Vietnam , Republic-of , Australian , Danish

Ascendis Pharma Introduces Vision 2030

Strategic roadmap to achieve blockbuster status for multiple products and expand the Company’s engine for future innovation COPENHAGEN, Denmark, Jan. 07, 2024 (GLOBE NEWSWIRE) Ascendis Pharma A/S (Nasdaq: ASND) today introduced selected 2024 corporate milestones and Vision 2030, its strategic roadmap through 2030. Ascendis President and CEO Jan Mikkelsen will present the update tomorrow, January 8, at the 42nd Annual J.P. Morgan Healthcare Conference. “With unwavering focus on our values of P

United-states , Denmark , China , Germany , Japan , Russia , Ukraine , Copenhagen , Køavn , Jan-mikkelsen , Ascendis-pharma , Melinda-baker

Financial Review: Nature's Sunshine Products (NASDAQ:NATR) and Puma Biotechnology (NASDAQ:PBYI)

Nature’s Sunshine Products (NASDAQ:NATR – Get Free Report) and Puma Biotechnology (NASDAQ:PBYI – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, profitability, analyst recommendations, institutional ownership and valuation. Insider & Institutional Ownership 76.1% of […]

California , United-states , Utah , America , Los-angeles , Nature-sunshine-products , Nature-sunshine-products-inc , Pfizer-inc , Therapeutics-asia-pte-ltd , Knight-therapeutics-inc , Puma-biotechnology-inc , Pint-pharma-international

Specialised Therapeutics signs exclusive license agreement with CanariaBio for new ovarian cancer therapy

Specialised Therapeutics signs exclusive license agreement with CanariaBio for new ovarian cancer therapy
asiabulletin.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from asiabulletin.com Daily Mail and Mail on Sunday newspapers.

Singapore , China , Brunei , Malaysia , Thailand , Vietnam , Republic-of , South-korea , Australia , New-zealand , Seoul , Soult-ukpyolsi

Specialised Therapeutics signs exclusive license agreement with CanariaBio for new ovarian cancer therapy

Specialised Therapeutics signs exclusive license agreement with CanariaBio for new ovarian cancer therapy
malaysiasun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from malaysiasun.com Daily Mail and Mail on Sunday newspapers.

Singapore , China , Thailand , Malaysia , South-korea , New-zealand , Brunei , Australia , Vietnam , Republic-of , Seoul , Soult-ukpyolsi

Specialised Therapeutics signs exclusive license agreement with CanariaBio for new ovarian cancer therapy

/PRNewswire/ Independent biopharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) has signed a license deal with Korea-based CanariaBio Inc.,.

Singapore , South-korea , Brunei , Thailand , New-zealand , Malaysia , China , Seoul , Soult-ukpyolsi , Vietnam , Republic-of , Australia

Specialised Therapeutics signs exclusive license agreement with CanariaBio for new ovarian cancer therapy

.. First ovarian cancer therapy for ST oncology portfolio .. Phase 2 study demonstrated oregovomab in combination with chemotherapy improved progression free survival by ~30 months compared to chemotherapy alone 1 ..

Singapore , Seoul , Soult-ukpyolsi , South-korea , China , Malaysia , New-zealand , Australia , Vietnam , Republic-of , Brunei , Thailand

Specialised Therapeutics signs exclusive license agreement with CanariaBio for new ovarian cancer therapy

Specialised Therapeutics signs exclusive license agreement with CanariaBio for new ovarian cancer therapy
vietnamtribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from vietnamtribune.com Daily Mail and Mail on Sunday newspapers.

Singapore , Vietnam , Republic-of , New-zealand , Seoul , Soult-ukpyolsi , South-korea , Australia , China , Brunei , Malaysia , Thailand